Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, ...

Q2 2025 Earnings Call Transcript July 29, 2025 Incyte Corporation beats earnings expectations. Reported EPS is $2.04, expectations were $1.39. Operator: Greetings, and welcome to the Incyte Second ...

The demand for treatments targeting myeloproliferative disorders is rising sharply, propelled by several key factors that underscore the market's rob ...

Incyte INCY is set to give its latest quarterly earnings report on Tuesday, 2025-07-29. Here's what investors need to know before the announcement. Analysts estimate that Incyte will report an ...

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with ...

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

DelveInsight's,“ Advanced Endometrial Cancer Pipeline Insight 2025” report provides comprehensive insights about 25+ ...

Incyte (Nasdaq:INCY) today reports 2025 second quarter financial results, and provides a status update on the Company’s clinical development portfolio. "As I begin my tenure as ...

"The absence of a statistically significant benefit of adjuvant chemotherapy in the ASTER 70s trial underlines the persistent ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

We report phase I results for obrixtamig (BI 764532), a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, in patients with previously treated DLL3-positive small cell lung cancer (SCLC), ...